NASDAQ:INFIInfinity Pharmaceuticals Stock Price, Forecast & News

Infinity Pharmaceuticals' stock was trading at $1.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, INFI stock has decreased by 12.9% and is now trading at $0.88. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Infinity Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Infinity Pharmaceuticals.

Infinity Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Infinity Pharmaceuticals.

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) announced its earnings results on Monday, May, 11th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.13) by $0.06. The biotechnology company had revenue of $0.43 million for the quarter, compared to the consensus estimate of $0.25 million. Infinity Pharmaceuticals had a negative net margin of 3,308.31% and a negative return on equity of 329.49%. View Infinity Pharmaceuticals' earnings history.

4 equities research analysts have issued 1-year price objectives for Infinity Pharmaceuticals' shares. Their forecasts range from $1.00 to $3.00. On average, they anticipate Infinity Pharmaceuticals' share price to reach $2.17 in the next year. This suggests a possible upside of 146.2% from the stock's current price. View analysts' price targets for Infinity Pharmaceuticals.

Media coverage about INFI stock has trended very negative this week, according to InfoTrie Sentiment. The research group ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Infinity Pharmaceuticals earned a media sentiment score of -3.5 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutInfinity Pharmaceuticals.

Infinity Pharmaceuticals saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 33,300 shares, a decrease of 8.0% from the April 30th total of 36,200 shares. Based on an average daily trading volume, of 160,500 shares, the short-interest ratio is presently 0.2 days. Approximately 0.1% of the company's stock are short sold. View Infinity Pharmaceuticals' Current Options Chain.

Some companies that are related to Infinity Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Immunomedics (IMMU). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Infinity Pharmaceuticals investors own include Continental Resources (CLR), Rex Energy (REXX), Aerie Pharmaceuticals (AERI), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), ImmunoGen (IMGN), Novavax (NVAX), Synergy Pharmaceuticals (SGYP), AVEO Pharmaceuticals (AVEO) and Bausch Health Companies (BHC).

Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI."

Infinity Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Acadian Asset Management LLC (1.03%) and Bleichroeder LP (0.00%). Company insiders that own Infinity Pharmaceuticals stock include Adelene Q Perkins, Bvf Partners L P/Il, Jeffery Kutok and Value Fund L P Biotechnology. View institutional ownership trends for Infinity Pharmaceuticals.

INFI stock was sold by a variety of institutional investors in the last quarter, including Bleichroeder LP, and Acadian Asset Management LLC. View insider buying and selling activity for Infinity Pharmaceuticals.

Shares of INFI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of INFI stock can currently be purchased for approximately $0.88.

Infinity Pharmaceuticals has a market capitalization of $50.54 million and generates $3.05 million in revenue each year. The biotechnology company earns $-47,060,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. Infinity Pharmaceuticals employs 25 workers across the globe.

The official website for Infinity Pharmaceuticals is www.infi.com.

Infinity Pharmaceuticals' mailing address is 1100 MASSACHUSETTS AVENUE FLOOR 4, CAMBRIDGE MA, 02138. The biotechnology company can be reached via phone at 617-453-1000 or via email at [email protected]